Express Pharma

DCGI panel to review today SII applications for Covovax’s use among kids aged 2-7 years, 7-11 years

The expert panel in its last meeting in April had sought more data from SII following its application seeking the Emergency Use Authorisation of Covovax for seven to 11 years.

0 156

The Subject Expert Committee (SEC) on COVID-19 of India’s drug regulator will today review the applications of Serum Institute of India (SII) seeking Emergency Use Authorisation (EUA) to use Covovax among those aged two to seven years and seven to 11 years, official sources said. The two applications were submitted by Prakash Kumar Singh, Director, Government and Regulatory Affairs, SII, on 16th March and 1st June.

The expert panel, in its last meeting in April, had sought more data from SII following its application seeking EUA of Covovax for kids aged seven to 11 years. The Drugs Controller General of India (DCGI) had approved Covovax for restricted use in emergency situations in adults on 28th Dec